Aerolytx

voice powered for aviation health

C L I N I C A L W H I T E P A P E R

AI-Powered Decision Support for Aviation Medical Examiners

Enhancing Pilot Mental Health Assessment,

HIMS Monitoring, and Return-to-Fly Decisions

How Vocal Biomarker Technology Can Help AMEs Protect Safety, Support Pilots, and Streamline the Most Challenging Aspect of Aeromedical Certification

For Aviation Medical Examiners, HIMS AMEs, and Aerospace Medicine Professionals

Prepared by Aerolytx | February 2026

Sources: FAA Guide for AMEs, DOT OIG, Mental Health ARC, HIMS, Canary Speech Clinical Data

Executive Summary

Aviation Medical Examiners occupy a unique and critical position in aviation safety. An AME is often the only medical professional who sees a pilot regularly, and AME examinations serve as the primary point of contact between a pilot's health status and the FAA's certification system [1][2]. Yet the tools available to AMEs for assessing mental health during routine examinations remain largely unchanged: a review of MedXPress responses, clinical observation, and questions that pilots have strong incentives to answer dishonestly [3][5].

Research confirms what AMEs likely see in practice: 81 percent of pilots will not use available mental health resources due to fear of career consequences [5]. Over 60 percent admit to delaying or avoiding medical care to protect their certificates [5]. Between 12.6% and 23.3% of active pilots meet clinical thresholds for depression, and 3–4.1% report suicidal ideation. Yet the FAA's aeromedical system depends almost entirely on pilot self-disclosure to identify these conditions—and decades of evidence demonstrate that pilots routinely conceal mental health symptoms due to fear of career consequences. When a pilot answers "no" to the mental health question on Form 8500-8, AMEs have no independent clinical tool to verify that answer. Each AME is asked to be a gatekeeper without a functioning gate. The DOT Office of Inspector General found that while the FAA has comprehensive procedures for evaluating psychological health, its ability to mitigate safety risks is fundamentally limited by pilots' reluctance to disclose [3].

Aerolytx, powered by Canary Speech's patented vocal biomarker platform, offers AMEs an objective, passive clinical decision-support tool that does not depend on self-disclosure. By analyzing acoustic features of natural speech during routine exam conversations or HIMS monitoring visits, the technology detects quantifiable indicators of depression, anxiety, cognitive fatigue, and stress—providing objective data to supplement clinical judgment [10][11].

> **For HIMS AMEs: Vocal biomarker monitoring provides longitudinal, quantitative data on pilot recovery that strengthens special issuance applications, supports return-to-fly decisions with objective evidence, and gives the FAA the measurable stability data it requires.**

The 2024 FAA Mental Health Aviation Rulemaking Committee (ARC) identified the need for technological innovation to improve early identification of at-risk pilots. The updated AME guidance issued in 2024 and 2025 gives greater latitude to certify pilots with uncomplicated depression and anxiety without automatic FAA deferral—but only if an AME can confidently assess their current mental status. Aerolytx provides the objective data needed to exercise that latitude responsibly.

This paper presents the case for integrating voice-based mental health screening into aeromedical practice, demonstrates how it aligns with updated FAA guidance and the SSRI protocol, and offers a roadmap for implementation that protects the AME, supports pilot-patients, and enhances aviation safety.

The Clinical Challenge: Why Self-Disclosure Fails

The FAA's aeromedical certification system is built on a foundational assumption: that pilots will truthfully disclose their health conditions. The MedXPress application includes direct questions about mental health history, and AMEs are trained to probe for symptoms during examinations [1][2]. In practice, however, this system has well-documented limitations [3][4].

What the Data Shows

- **81% of pilots surveyed** said they would not use available mental health resources due to fear of losing their medical certificates [3][5].
- **Over 60% of pilots** admitted to delaying or avoiding medical care to protect their ability to fly [5].
- **At least 24 commercial pilots** told Reuters they were reluctant to disclose mental health issues—even minor or treatable ones—fearing immediate grounding and a lengthy, costly review [5].
- **The FAA Mental Health ARC** identified seven primary barriers to disclosure: fear of career loss, stigma, financial burden, process length, process uncertainty, lack of information, and complexity of the certification system [4].
- **The DOT Inspector General** confirmed that FAA's ability to mitigate safety risks is limited by pilots' reluctance to disclose, and recommended that FAA "encourage pilots with mental health issues to disclose and seek treatment" [3].

The Germanwings tragedy of 2015 remains the starkest illustration. The copilot had suffered severe depression since 2008. His medical certificate was renewed annually. Two weeks before deliberately crashing the aircraft and killing 150 people, a physician recommended psychiatric hospitalization—but no aviation authority was informed [12][14]. The system's reliance on self-disclosure and physician reporting failed at every level.

The AME's Dilemma: High Stakes, Limited Tools

AMEs face a practical challenge during every examination: a limited window—often 20 to 30 minutes—to assess an airman's overall fitness to fly, including mental health [2]. AMEs are trained to observe for signs of psychological distress, but they are working with a patient who may be actively concealing symptoms and who knows exactly which answers will keep them certified [3][5]. The AME serves simultaneously as the pilot's physician and the FAA's gatekeeper, a dual role that inherently inhibits candid disclosure [4].

The AME Guide directs examiners to "ask further questions about mental health conditions or symptoms" based on the examination, and to defer to the Office of Aerospace Medicine if concerns arise [1]. But what if the pilot presents well despite underlying conditions? Depression, anxiety, and early cognitive decline can be masked by motivated individuals during brief clinical encounters [13]. AMEs need tools that go beyond what observation and self-report can tell them.

Every time an AME conducts an aeromedical examination involving potential mental health concerns, they face a decision with profound consequences:

Defer the application → The pilot is immediately grounded, faces 6–18 months without income while awaiting FAA review, incurs $15,000–$30,000 in out-of-pocket costs for psychiatric evaluation and neuropsychological testing, and may never return to flying [11][12][13]. For many pilots, deferral means financial ruin and the end of a career they have spent decades building.

Issue the certificate → If an assessment is wrong—if the pilot is experiencing significant untreated depression, suicidal ideation, or acute psychological distress—the AME has cleared someone to operate an aircraft while cognitively impaired. The safety consequences are unacceptable. The legal and professional liability is severe.

There is no low-stakes option. Every decision is a bet on incomplete information, made under pressure, with life-and-death implications.

What You Have to Work With

The FAA provides medical examiners with several tools for mental health screening during the aeromedical examination:

FAA Form 8500-8, Item 18. The pilot checks a box indicating whether they have ever been diagnosed with or currently have "mental disorders of any sort; depression, anxiety, etc."[14] This is self-reported information from an individual who knows that checking "yes" will immediately ground them.

Interview and observation. During a 20–45-minute examination focused primarily on physical health parameters, AME's can observe the pilot's demeanor, ask clarifying questions, and use clinical judgment to assess their mental state.

AME Decision Tools. The FAA has provided structured decision tools for uncomplicated anxiety and depression that allow you to issue certificates without deferral if specific criteria are met: no medication for two years, no suicidal ideation, no hospitalizations, and satisfactory responses to screening questions [9][10][15].

Your clinical experience. AME's bring years of medical training and experience evaluating patients—but generally they are not a psychiatrist and typically have no access to prior mental health treatment records, and they are evaluating individuals who are highly motivated to appear healthy.

The Detection Gap

The fundamental problem is this: the pilots most at risk are the ones least likely to disclose. Research consistently shows that fear of career loss, financial hardship, and stigma prevent pilots from reporting mental health conditions [4][5][16]. A 2024 qualitative study found that every interviewed pilot expressed hesitation to disclose psychological symptoms, despite formal assurances of support [5]. Pilots know that colleagues who disclosed depression or anxiety faced prolonged grounding, expensive evaluations, and permanent "special issuance" status [11][12].

Medical examiners are expected to detect conditions that pilots are actively concealing, using tools that depend entirely on those same pilots volunteering the information. After Germanwings Flight 9525, the DOT Inspector General concluded that "FAA's ability to mitigate safety risks is limited by

pilots' reluctance to disclose mental health conditions"[17]. That limitation falls directly on the AME—who must somehow bridge the gap between what pilots report and what is actually true.

The Workload Reality

Mental health evaluations are time-intensive and administratively burdensome. When there is suspected a mental health condition or a pilot discloses prior treatment:

- AME must determine whether the condition meets deferral criteria under FAR Part 67 and current FAA policy [14][18].
- AME must explain to the pilot that deferral means immediate grounding and months of uncertainty.
- AME must complete detailed documentation for FAA review, including your clinical rationale.
- AME must navigate the pilot's emotional response—often anger, fear, or pleading—while maintaining your professional judgment.

For cases involving depression or anxiety with SSRI use, the complexity increases further: AME's must determine eligibility for the SSRI protocol, coordinate with a HIMS-trained AME if they are not HIMS-qualified, ensure the pilot understands the 6-month stabilization requirement, and manage the extensive documentation requirements [11][19][20].

This workload falls disproportionately on a relatively small number of AMEs. Many AMEs, understandably, prefer to avoid the complexity entirely—and there is evidence that some AMEs "lead" pilots toward answering questions in ways that avoid triggering deferrals, rather than conducting rigorous mental health assessments [5]. This is not malfeasance—it is a rational response to an impossible burden.

THE REGULATORY LANDSCAPE: EVOLVING EXPECTATIONS

The 2024 Mental Health ARC Recommendations

The FAA's 2024 Mental Health & Aviation Medical Clearances Aviation Rulemaking Committee produced 24 recommendations aimed at improving identification and treatment of pilot mental health conditions [4]. Several recommendations directly impact the work of an AME:

Recommendation 3: Encourage Pilots to Seek Help. The ARC called for programs that reduce barriers to mental health care and create safer pathways for pilots to come forward. This shifts the emphasis from punitive grounding toward early intervention and support.

Recommendation 5: Expedite Reviews and Decisions. The ARC recognized that current FAA review timelines—often 6–12 months or longer for psychiatric cases—impose severe hardship on pilots and discourage disclosure [4][12][13]. Faster turnaround requires better information up front, reducing the need for iterative requests and re-evaluation.

Recommendation 6: Revise Requirements for Depression and Anxiety. The ARC recommended modernizing certification standards for pilots on monotherapy for depression or anxiety, moving away from blanket prohibitions toward individualized, risk-based assessments.

Recommendation 11: Technology and Innovation. The ARC explicitly called for exploring technological solutions to improve mental health detection and support—acknowledging that the current self-disclosure system is insufficient [4].

These recommendations reflect a fundamental policy shift: the FAA recognizes that the old model—defer first, evaluate later—is failing. The emphasis is moving toward early detection, faster resolution, and keeping safe pilots flying while identifying truly high-risk individuals before they cause accidents.

Updated AME Guidance: Greater Autonomy, Greater Responsibility

In June 2024 and April 2025, the FAA updated its guidance to AMEs on "uncomplicated anxiety, depression, and related conditions"[9][10]. The key change: AMEs now have authority to issue medical certificates without FAA deferral for pilots with histories of up to two mental health diagnoses, provided specific criteria are met:

- No psychotropic medication for at least two years
- No suicidal ideation, hospitalization, or psychotic symptoms
- Satisfactory responses to the FAA's Anxiety/Depression Decision Tool questionnaire
- No additional concerns raised during the AME examination [9][10][15]

While a positive development—it allows AME's to keep pilots flying when they meet objective low-risk criteria, it also increases AME responsibility. Medical examiners must now make certification decisions that previously would have been deferred to FAA headquarters. AME's must be confident that the pilot's self-reported history is accurate and complete. Pilots must be assessed whether their current mental state justifies certification—without the psychiatric expertise, neuropsychological testing, or longitudinal data that the FAA's Aerospace Medicine Division would normally review.

The updated guidance gives AME's greater latitude—but only if they have the tools to exercise that latitude responsibly.

The SSRI Protocol and HIMS AME Requirements

For pilots currently taking SSRIs or SNRIs for depression or anxiety, the FAA's special issuance protocol creates a pathway to certification—but it is complex, time-intensive, and requires specialized AME involvement [11][19][20][21].

Basic SSRI Protocol requirements:

- Pilot must be on one of the approved medications (fluoxetine, sertraline, citalopram, escitalopram, or several newer additions)
- Stable dose for at least 6 months with no side effects
- Comprehensive psychiatric evaluation by board-certified psychiatrist
- Neuropsychological testing demonstrating no cognitive impairment
- Ongoing monitoring by a HIMS-trained AME
- Special issuance medical certificate, typically valid for 6–12 months [11][19][20]

HIMS AME's bear direct responsibility for coordinating the pilot's evaluation, submitting the special issuance package, and providing ongoing monitoring reports to the FAA. If AMS is not HIMS-trained, they must refer the pilot to a HIMS AME, adding another layer of complexity and delay.

Current turnaround times from initial deferral to special issuance approval range from 6 months to over a year, even with complete documentation [12][13][22]. During this time, the pilot is grounded and not earning income. The process costs $15,000–$30,000 out of pocket, rarely covered by insurance [11][12].

The SSRI protocol represents progress—but it remains a high-friction, high-cost pathway that pilots avoid until their symptoms become severe. What the system lacks is a mechanism for early detection and intervention before pilots reach the point of needing psychiatric medication and formal FAA review.

Vocal Biomarker Technology: Clinical Foundation

Canary Speech's vocal biomarker platform, integrated into Aerolytx, represents an emerging class of digital biomarker technology that analyzes acoustic and prosodic features of speech to detect physiological and psychological states [10][11]. The technology does not analyze speech content—it analyzes how a person speaks, identifying patterns correlated with specific conditions.

Technical Capabilities

Capability	Clinical Relevance
40-second sample	Minimal disruption to exam workflow. Analysis from conversational speech during routine exam—no separate test required.
3-second processing	Near real-time results available during the exam visit. No waiting for lab results or separate appointments.
12 million data elements	Thousands of acoustic markers analyzed per sample, including pitch variation, speech rate, pause patterns, filler word frequency, vocal energy, and prosodic features.
Quantifiable Voice Scores	Objective numerical scores for stress, mood, energy, and cognitive function. Comparable across time points for longitudinal monitoring.
Early detection	Canary Ambient™ identifies indicators before observable symptoms appear—critical for conditions that pilots are skilled at masking.
CPT code validated	Recognized as medical biomarkers with CPT codes, establishing clinical legitimacy and insurance reimbursement eligibility.

HIPAA-compliant	Azure-based infrastructure with full HIPAA compliance. Speech patterns analyzed—conversation content is not recorded or stored.

The key clinical distinction is objectivity. Unlike questionnaires (PHQ-9, GAD-7) that depend on honest self-report, vocal biomarkers measure physiological correlates of mental health conditions through involuntary speech patterns that are extremely difficult to consciously control or fake. A pilot can answer “I feel fine” while their voice acoustics tell a different story.

Integration Into AME Practice

Routine Medical Examinations

Vocal biomarker screening integrates seamlessly into the standard AME examination workflow:

1. **During the exam:** As the AME conducts the standard history and physical, the Aerolytx system passively analyzes the pilot’s speech patterns during the conversational exchange. No additional questions or procedures are required.
2. **Immediate scoring:** Within seconds, the AME receives Voice Scores assessing mood, stress, cognitive function, and energy levels—displayed alongside the pilot’s historical baseline if available.
3. **Clinical decision support:** Scores outside normal ranges flag potential concerns for review. This is not a diagnosis—it is an additional data point informing clinical judgment about whether further evaluation is warranted.
4. **Documentation:** Vocal biomarker data can be incorporated into examination records, providing objective evidence supporting the certification or deferral decision.

For the majority of healthy pilots, vocal biomarker screening simply confirms what the clinical assessment already indicates—providing an additional layer of confidence. For the small percentage of pilots who may be concealing symptoms, it offers an objective signal that subjective assessment alone cannot provide.

HIMS Program Monitoring

For HIMS AMEs managing pilots in substance abuse recovery or on approved medications, vocal biomarker monitoring addresses several critical needs:

Longitudinal Recovery Tracking

The HIMS program requires ongoing monitoring to verify sustained recovery and fitness for flight. Current monitoring relies on sponsor reports, aftercare group participation, random testing, and periodic psychiatric/psychological evaluations. Vocal biomarker data adds a continuous, objective dimension:

- **Monthly or visit-based voice samples** create a quantitative recovery trajectory that the FAA can review alongside existing documentation.
- **Deviation detection:** Sudden changes in Voice Scores between visits—even when the pilot presents well clinically—can prompt closer evaluation before problems escalate.
- **Relapse indicators:** Research correlates specific vocal pattern changes with substance use relapse and depressive episode onset. Early detection supports the HIMS program's 85% sustained abstinence success rate [8][9].

Special Issuance Support

The special issuance process requires substantial documentation demonstrating that a pilot's condition is stable and well-managed. Vocal biomarker data strengthens these applications:

- **Quantitative stability evidence:** Instead of relying solely on clinical opinion ("pilot appears stable"), AMEs can provide numerical Voice Score trends showing consistent, objective improvement over time.
- **Pre-P&P confidence:** Before referring a pilot for the costly psychiatric and neuropsychological (P&P) evaluation, voice data can help the AME assess whether the pilot is genuinely ready—potentially avoiding premature referrals that result in failed evaluations and repeated testing.
- **FAA submission documentation:** Longitudinal vocal biomarker reports provide the kind of measurable, time-stamped evidence the Office of Aerospace Medicine reviews when making certification decisions.
- **Post-certification monitoring:** During the three-to-seven-year monitoring period following special issuance, voice analysis at each visit provides ongoing objective verification of continued fitness.

SSRI Protocol Monitoring

With the FAA's expanded antidepressant list (now including Cymbalta, Effexor, and Pristiq) and the reduced stabilization period from six to three months, more pilots will be navigating the SSRI pathway [2][6]. Vocal biomarker monitoring is particularly valuable here:

- **Medication response tracking:** Voice Scores can objectively track the pilot's response to medication during the stabilization period, providing evidence that the prescribed treatment is achieving desired effects.
- **Dosage change detection:** Medication changes or dosage adjustments—which can trigger additional FAA review—are often reflected in vocal biomarker patterns before clinical symptoms are apparent.
- **Three-month milestone documentation:** At the critical three-month mark when pilots become eligible for return-to-fly testing, Voice Score trends provide objective evidence supporting readiness.

The Opportunity for AME Practices

The landscape of aviation mental health is shifting rapidly. The Mental Health in Aviation Act authorizes $13.74 million annually for AME recruitment and training, including mental health specialists [7]. The FAA is expanding AME authority to issue certificates for treated mental health conditions [2][6]. HIMS caseloads have increased from ~100 to 200–250 new cases per year [8]. And only 204 AMEs are HIMS-certified, with just 48 handling the majority of cases [8].

AMEs who adopt objective screening tools early position themselves at the forefront of this evolution:

- **Practice differentiation:** Offering vocal biomarker screening distinguishes an AME practice among the approximately 2,500 active AMEs—particularly valuable for attracting HIMS cases and airline contracts.
- **Clinical confidence:** Objective data supporting certification decisions reduces the uncertainty inherent in brief examination encounters with motivated patients.
- **Pilot trust:** Paradoxically, pilots may be more comfortable with objective screening than with probing questions. A passive voice analysis during conversation feels less adversarial than direct mental health inquiries.
- **FAA alignment:** The Mental Health ARC recommended reducing barriers and improving screening. Tools that detect conditions without relying on self-disclosure directly address the ARC's core finding.
- **Medicolegal protection:** Documented use of objective screening tools demonstrates thoroughness in fitness-for-duty assessments—a valuable record should questions arise about a pilot an AME has certified.
- **Revenue opportunity:** Vocal biomarker screening with validated CPT codes creates a reimbursable clinical service that adds value to both routine and HIMS examinations.

Implementation for AME Practices

Getting Started

5. **Technical setup:** Aerolytx is API-driven and runs on standard devices (tablet, smartphone, computer). No specialized hardware. Setup integrates with existing exam room workflows.
6. **Baseline collection:** Begin collecting voice samples during routine exams to build a baseline database. Initial samples establish each pilot's normal range for future comparison.
7. **Clinical protocol development:** Define how Voice Score data will be used in decision-making—as one input among many, never as a standalone diagnostic tool.

8. **Pilot communication:** Brief pilots on the technology during their exam. Frame it as an enhancement to their care: “This gives the AME objective data to support keeping pilots flying.”

Workflow Integration

Exam Type	Vocal Biomarker Application
Routine 1st/2nd/3rd Class	Passive analysis during exam conversation. Scores reviewed alongside MedXPress responses. Normal results confirm clinical assessment. Abnormal results prompt further evaluation.
HIMS Initial Evaluation	Comprehensive baseline establishment. Detailed Voice Score report documenting current state for FAA submission. Comparison against population norms.
HIMS Follow-Up Visits	Longitudinal tracking. Voice Score trends appended to monitoring documentation. Deviation alerts flag concerns between visits.
SSRI Protocol Visits	Medication response monitoring. Three-month stabilization documentation. Dosage change sensitivity detection.
Pre-P&P Assessment	Readiness screening before expensive psychiatric/neuropsychological evaluation referral. Objective evidence supporting referral timing decision.
Special Issuance Renewal	Annual or semi-annual Voice Score comparison to prior visits. Trend reports for FAA submission. Continued fitness verification.

Important Clinical Boundaries

Aerolytx is designed as a clinical decision-support tool with clearly defined boundaries:

- **Not a diagnostic instrument:** Voice Scores are screening indicators, not diagnoses. Abnormal results indicate the need for further clinical evaluation, not automatic deferral.
- **Supplements, does not replace, clinical judgment:** The AME remains the clinician. Vocal biomarker data is one input alongside the physical examination, history review, and professional assessment.
- **Privacy-preserving:** Speech content is not recorded. Only acoustic patterns are analyzed. Pilots retain control over how their data is shared.
- **Not an FAA-mandated test:** Currently positioned as a voluntary clinical tool. Integration into FAA protocols would require future regulatory action.

Regulatory Context and Future Direction

The regulatory environment is moving toward exactly the kind of objective, scalable screening that vocal biomarker technology provides:

- **Mental Health ARC (2024):** The 24 consensus recommendations emphasized reducing barriers to disclosure, improving screening accuracy, and creating nonpunitive pathways. Objective screening tools that bypass self-disclosure align directly with these recommendations [4].
- **FAA Reauthorization Act (2024):** Created task forces to review aeromedical certification, evaluate the special issuance process, and modernize the medical portal—signals that the FAA is actively seeking better tools and processes [6][7].
- **Mental Health in Aviation Act (2025):** Would require FAA to implement ARC recommendations, fund AME training, and conduct annual reviews of special issuance procedures. This legislation creates both the mandate and the funding for improved screening tools [7].
- **Expanded AME Authority (May 2024):** AMEs can now issue certificates on the spot for up to two listed mental health conditions treated with psychotherapy and/or approved medication [2][6]. This expanded authority increases the importance of having objective data to support on-the-spot decisions.
- **Reduced SSRI stabilization (December 2025):** The three-month window creates a need for efficient, objective monitoring tools to document medication response during the abbreviated stabilization period [6].

The trajectory is clear: the FAA is moving toward more nuanced, evidence-based mental health assessment and certification. AMEs who adopt objective screening tools now will be well-positioned as these reforms take effect.

Conclusion

Aviation Medical Examiners serve a vital role in protecting aviation safety while supporting the pilots in their care. The current system places AMEs in a difficult position: tasked with detecting mental health conditions in patients who have every incentive to conceal them, using tools that depend on the very self-disclosure the system discourages.

Vocal biomarker technology offers a way through this impasse. By providing objective, quantifiable mental health indicators from natural conversational speech, Aerolytx equips AMEs with data that clinical observation alone cannot capture. For HIMS cases, it provides the longitudinal recovery documentation that strengthens special issuance applications and gives the FAA confidence in return-to-fly decisions. For routine exams, it adds a passive screening layer that catches what self-report misses.

The result is better for everyone: safer skies, better-supported pilots, stronger clinical decisions, and a more robust certification process. Aerolytx is not replacing AME expertise—it is amplifying it with the objective data the current system lacks.

> **AMEs interested in exploring how vocal biomarker screening can enhance their practice are invited to contact Aerolytx at info@aerolytx.com to discuss a clinical partnership, or request a demonstration of the platform integrated into a simulated examination workflow.**

References

[1] FAA. Guide for Aviation Medical Examiners. faa.gov/ame_guide

[2] FAA. Pilot Mental Fitness. faa.gov/pilot-mental-fitness

[3] DOT OIG. FAA Conducts Comprehensive Evaluations of Pilots' Mental Health but Barriers to Disclosure Remain. Report AV2023037. July 2023.

[4] FAA. Mental Health and Aviation Medical Clearances ARC. Final Report. April 2024.

[5] Reuters / Insurance Journal. Airline Pilots Hide Mental Health Struggles to Keep Flying. December 2025.

[6] NBAA. FAA Is Removing Some Barriers to Pilot Mental Health Treatment. January 2026.

[7] Mental Health in Aviation Act of 2025 (H.R. 2591 / S. 3257). Congress.gov.

[8] Kansas Aviation Medicine. FAA HIMS Program statistics and success rates. kansasaviationmedicine.com

[9] HIMS Program. FAA Certification process. himsprogram.com/faa-certification

[10] Canary Speech. How It Works. canaryspeech.com/how-it-works

[11] Microsoft Customer Stories. Canary Speech and Azure AI Services. 2024.

[12] BEA (France). Final Report—Germanwings Airbus A320-211 Accident. 2016.

[13] Frontiers in Psychiatry. Reflecting on the Germanwings Disaster: Depression and Suicide in Commercial Airline Pilots. 2018.

[14] JAAPL. Psychiatry and Fitness to Fly After Germanwings. 2019.